Skip to main content
Caplight Logo









Shanghai RNACure Biopharma Co., Ltd.

Shanghai RNACure Biopharma Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttps://rnacure.com/

Last Round

Series A

Extension

May 23, 2022

Company Overview

Shanghai RNACure Biopharma Co., Ltd. is a biotechnology company that develops mRNA-based vaccines and therapeutic platforms for infectious diseases, immuno-oncology, and rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

mRNA therapeuticsmRNA vaccineslipid nanoparticleLNPbiotech platformgene medicinemRNA deliverydrug discoveryCMCbiopharmamRNA techvaccine developmentsequence designRNA medicinebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai RNACure Biopharma Co., Ltd. Comparables

Compare Shanghai RNACure Biopharma Co., Ltd. with similar companies based on industry and business-model similarity.

Shanghai RNACure Biopharma Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Innovac Therapeutics
86%
RNAimmune
84%
WestGene Biopharma
84%

Shanghai RNACure Biopharma Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMay 23, 2022
Series ASep 27, 2021
Pre SeedMar 29, 2021
AngelJan 11, 2021

Shanghai RNACure Biopharma Co., Ltd. Investors

Notable investors and investment history

Shanghai RNACure Biopharma Co., Ltd. investors
InvestorRounds
Bencao CapitalSeries A
Guoke Jiahe CapitalPre Seed
Shine AssetSeries A
CoStone CapitalSeries A Extension
LYZZ CapitalPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 23, 2022

    CoStone Capital and China State-Owned Capital Venture Investment Fund participated.

  • Mar 29, 2021

    Raised capital from Guoke Jiahe Capital and LYZZ Capital.

Shanghai RNACure Biopharma Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai RNACure Biopharma Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai RNACure Biopharma Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range11
Year FoundedN/A
Last FundingMay 23, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?